Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.

@article{Belch1983DazoxibenAT,
  title={Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.},
  author={Jill J F Belch and J L Cormie and Paul Newman and M Mclaren and J. C. Barbenel and Hilary Capell and P J Leiberman and Charles D. Forbes and Cameron M Prentice},
  journal={British journal of clinical pharmacology},
  year={1983},
  volume={15 Suppl 1},
  pages={113S-116S}
}
1 UK-37248 (dazoxiben), an orally active thromboxane synthetase inhibitor, was evaluated in a double-blind trial of patients with severe Raynaud's syndrome. 2 Twenty patients were enrolled in the study. Eleven of these patients received dazoxiben 400 mg day and nine received matching placebo capsules. Treatment was given for 6 weeks and the patients reviewed at 2 weekly intervals during the study. 3 Assessment of response was judged by clinical symptoms and hand temperature measurements… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…